N/A N=49 Probiotics for Liver Cirrhosis With Portal Hypertension
Liver Cirrhosis · Portal Hypertension
Primary: Admission Due to Complications Related to Portal Hypertension — 2; 3 participants — p=0.25
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=70 Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
HIV Infections
Primary: Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 12 — -2.0; -0.5; -3.1; -1.2 percent of CD8 expressing HLA-DR+/CD38+ — p=0.428
N/A N=122 Vitamin D in HIV-Infected Patients on HAART
Vitamin D Deficiency · HIV
Primary: Success Rate in Achieving a 25(OH)D Level ≥30ng/mL After 12 Weeks of Oral Vitamin D Supplementation. — 81 percentage of participants — p=<0.05
N/A N=239 Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer
Colorectal Cancer · Hereditary Non-polyposis Colon Cancer
Primary: Impact of Standard Informed Consent vs CD-ROM Educational Intervention on Knowledge About Microsatellite Instability (MSI) Testing — 4.07; 4.17 units on a scale
Phase 1 N=6 Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled Prucalopride Succinate — 96.5 ng*h/ml
Phase 2 N=69 Phase II Trial of Ontak With Metastatic Melanoma
Malignant Melanoma
Primary: Positive Response Defined as Clinical Complete Response, Partial Response or Stable Disease (Persisting for at Least 4 Weeks) as Measure by Modified RECIST Criteria — 16…
N/A N=27 Light Therapy Treatment in Parkinson's Disease Patients With Daytime Somnolence
Parkinson's Disease · Sleep Disorder; Excessive Somnolence
Primary: Change in the Epworth Sleepiness Scale (ESS) Scores Comparing the Bright Light Exposure With Dim-red Light Exposure. — 4.46; 1.77 score — p=0.0211
Phase 3 N=60 Dronabinol Naltrexone Treatment for Opioid Dependence
Opioid Dependence
Primary: Opiate Withdrawal Measured by the Subjective Opiate Withdrawal Scale (SOWS) . — 11.16; 13.36 units on a scale
N/A N=103 Effects of Probiotics in Immune System of Healthy Adults
Conditions Influencing Health Status
Primary: Gastrointestinal Tolerance After Probiotic Consumption. — 20; 20; 20; 20 participants
Phase 3 N=1,809 Comparative Study of Three NNRTI-Sparing HAART Regimens
HIV Infection
Primary: Cumulative Probability of First Virologic Failure by Week 96 — 13; 10; 15 cumulative probability per 100 persons
Phase 4 N=100 Study of Two Different Starting Doses of Methotrexate When Starting Treatment in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Mean Change in the DAS28-3 (Disease Activity Score Using 28 Joints and Using 3 Variables) - Difference Between This Score at 12 Weeks and This Score at Baseline — -0.47…
N/A N=30 Comparison of Surgical Time and Efficiency of Total Knee Arthroplasty
Osteoarthritis, Knee
Primary: Surgical Procedure Time to Compare Skin-to-Skin Time for Conventional Versus TruMatch® Primary Total Knee Replacements — 65.8; 67.3 minutes — p=0.54
Phase 3 N=102 A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)
Pneumococcal Disease
Primary: Geometric Mean Concentration of Antibodies to Pneumococcal Serotypes Contained in the Vaccine — 0.2; 0.2; 4.1; 2.5 ug/mL
Phase 2 N=22 Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus
Primary: Area Under the Insulin Concentration-time Curve for the First Hour (AUC0-60) — 12346.67; 8297.62; 11607.65; 4331.76 nanomole*minute per liter (nmol*min/L) — p=0.0011
Phase 4 N=21 Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
Schizophrenia
Primary: Change in Alternative Beliefs Assessment — 14.05; 10.70 units on a scale